We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study
Read MoreHide Full Article
BioNTech SE (BNTX - Free Report) announced that it has expanded its current strategic collaboration agreement with Regeneron Pharmaceuticals (REGN - Free Report) to begin a third cancer study.
With the expanded agreement, BioNTech is looking to evaluate its FixVac candidate, BNT116, in combination with Regeneron’s PD-1 inhibitor, Libtayo (cemiplimab), for the treatment of patients with advanced non-small-cell lung cancer (“NSCLC”), the most common type of lung cancer.
Per the latest agreement, BioNTech and Regeneron will equally share all development costs for the studies on the combo of BNT116 plus Libtayo. The companies are planning to begin a phase I/II study evaluating BNT116 plus Libtayo in the first-line treatment setting for advanced NSCLC.
The expanded partnership is looking to check whether BNT116+Libtayo is able to further enhance the efficacy and safety in addressing advanced NSCLC as compared to Libtayo, both as a monotherapy and in combination with chemotherapy.
Additionally, BioNTech plans to fund and run a phase I study – LuCa-MERIT-1 – investigating BNT116 plus Libtayo in further subpopulations with NSCLC under a separate agreement.
Shares of BioNTech have plunged 50.3% so far this year compared with the industry’s decline of 19.3%.
Image Source: Zacks Investment Research
Notably, advanced NSCLC, for which BioNTech and Regeneron have expanded their collaboration, is the third tumor type the companies are studying.
Under the existing collaboration, the companies are already evaluating BioNTech’s another FixVac candidate, BNT111, in combination with Libtayo in a phase II study for treating advanced melanoma. BioNTech is also investigating the combination of its FixVac candidate, BNT112, plus Libtayo in a phase I study for the treatment of prostate cancer.
We remind investors that Regeneron is jointly developing Libtayo in partnership with Sanofi (SNY - Free Report) .
While Regeneron records net product sales of Libtayo in the United States, Sanofi records the same outside the country. Both REGN and SNY equally share profits/losses in connection with global sales of Libtayo.
Image: Bigstock
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study
BioNTech SE (BNTX - Free Report) announced that it has expanded its current strategic collaboration agreement with Regeneron Pharmaceuticals (REGN - Free Report) to begin a third cancer study.
With the expanded agreement, BioNTech is looking to evaluate its FixVac candidate, BNT116, in combination with Regeneron’s PD-1 inhibitor, Libtayo (cemiplimab), for the treatment of patients with advanced non-small-cell lung cancer (“NSCLC”), the most common type of lung cancer.
Per the latest agreement, BioNTech and Regeneron will equally share all development costs for the studies on the combo of BNT116 plus Libtayo. The companies are planning to begin a phase I/II study evaluating BNT116 plus Libtayo in the first-line treatment setting for advanced NSCLC.
The expanded partnership is looking to check whether BNT116+Libtayo is able to further enhance the efficacy and safety in addressing advanced NSCLC as compared to Libtayo, both as a monotherapy and in combination with chemotherapy.
Additionally, BioNTech plans to fund and run a phase I study – LuCa-MERIT-1 – investigating BNT116 plus Libtayo in further subpopulations with NSCLC under a separate agreement.
Shares of BioNTech have plunged 50.3% so far this year compared with the industry’s decline of 19.3%.
Image Source: Zacks Investment Research
Notably, advanced NSCLC, for which BioNTech and Regeneron have expanded their collaboration, is the third tumor type the companies are studying.
Under the existing collaboration, the companies are already evaluating BioNTech’s another FixVac candidate, BNT111, in combination with Libtayo in a phase II study for treating advanced melanoma. BioNTech is also investigating the combination of its FixVac candidate, BNT112, plus Libtayo in a phase I study for the treatment of prostate cancer.
We remind investors that Regeneron is jointly developing Libtayo in partnership with Sanofi (SNY - Free Report) .
While Regeneron records net product sales of Libtayo in the United States, Sanofi records the same outside the country. Both REGN and SNY equally share profits/losses in connection with global sales of Libtayo.
Zacks Rank & Stock to Consider
BioNTech currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Vertex Pharmaceuticals Incorporated (VRTX - Free Report) , which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Vertex’s earnings estimates have been revised 9% upward for 2022 over the past 60 days. The VRTX stock has gained 8.7% year to date.
Vertex’s earnings have surpassed estimates in each of the trailing four quarters.